News - Chiesi Farmaceutici

Filter

Current filters:

Chiesi Farmaceutici

Popular Filters

Chiesi links with UCL to test a novel therapeutic for birth asphyxia

Chiesi links with UCL to test a novel therapeutic for birth asphyxia

10-06-2014

Privately-held Italian drugmaker Chiesi Farmaceutici has entered into a collaboration with University…

Chiesi FarmaceuticiLicensingmelatoninNeurologicalPharmaceuticalResearch

Six-year follow-up data from Glybera treated patients

Six-year follow-up data from Glybera treated patients

17-03-2014

Netherlands-based human gene company uniQure and privately-held Italian drugmaker Chiesi Farmaceutici…

BiotechnologyChiesi FarmaceuticiGlyberaRare diseasesResearchuniQure

Study shows Fostair has comparable efficacy to Seretide in asthma patients

Study shows Fostair has comparable efficacy to Seretide in asthma patients

20-01-2014

A study has shown that asthma patients may be switched from Seretide to Fostair at an equivalent or lower…

Chiesi FarmaceuticiFostairGlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonarySeretideUK

Chiesi Farmaceutici to acquire full ownership of Cornerstone Therapeutics

17-09-2013

Privately-held Italian drugmaker Chiesi Farmaceutici and specialty US firm Cornerstone Therapeutics (Nasdaq:…

Chiesi FarmaceuticiCornerstone TherapeuticsMergers & AcquisitionsPharmaceutical

Chiesi expands rare disease portfolio with acquisition

26-08-2013

Privately-owned Italian drugmaker Chiesi Group has signed, through its UK affiliate, a definitive agreement…

BiotechnologyChiesi FarmaceuticiLamazymMergers & AcquisitionsPharmaceuticalRare diseasesZymenex

Italy's Chiesi gains rights to uniQure's Glybera

12-07-2013

Netherlands-based venture capital backed human gene therapy firm uniQure has signed collaboration agreements…

BiotechnologyChiesi FarmaceuticiGlyberaLicensingMergers & AcquisitionsPharmaceuticaluniQure

Italy's Chiesi eyes Russian expansion

30-04-2013

Privately held Italian drugmaker Chiesi Farmaceutici is considering a massive expansion into the Russian…

Chiesi FarmaceuticiEuropeGenericsMarkets & MarketingPharmstandardProductionRespiratory and Pulmonary

Italy's Chiesi seeking to take full control of Cornerstone Thera

20-02-2013

Shares of USA-based Cornerstone Therapeutics (Nasdaq: CRTX) jumped 19.5% to $6.55 in after-hours trading…

Chiesi FarmaceuticiCornerstone TherapeuticsMergers & AcquisitionsPharmaceutical

Cornerstone Thera gets US rights to Chiesi's Bethkis

11-11-2012

USA-based specialty pharma firm Cornerstone Therapeutics Inc. (Nasdaq: CRTX) says it has entered into…

BethkisChiesi FarmaceuticiCornerstone TherapeuticsGenericsLicensingNorth AmericaPharmaceuticalRare diseasesRespiratory and Pulmonary

Chiesi Farmaceutici establishes new Mexico affiliate, views growth

25-10-2012

Privately-owned Italian drugmaker Chiesi Farmaceutici says it has recently opened its 25th affiliate,…

Chiesi FarmaceuticiFinancialMarkets & MarketingPharmaceuticalResearchSouth America

Veloxis Pharma in LCP-Tacro deal with Chiesi

07-10-2012

Denmark's Veloxis Pharmaceuticals A/S (OMX: VELO) has entered into an exclusive distribution agreement…

Chiesi FarmaceuticiEuropeImmunologicalsLCP-TacroLicensingPharmaceuticaltacrolimusVeloxis Pharmaceuticals

FDA advisory negative on Cornerstone's lixivaptan

17-09-2012

The US Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) last…

BiotechnologyCardio-vascularChiesi FarmaceuticiCornerstone TherapeuticslixivaptanNorth AmericaPharmaceuticalRegulation

Kamada in distribution deal with Chiesi for Europe, Turkey and former CIS countries

08-08-2012

Israeli biopharma company Kamada (KMDA: TA) has entered into an exclusive agreement with privately-owned…

alpha-1 antitrypsinChiesi FarmaceuticiEuropeKamadaLicensingPharmaceuticalRare diseases

Chiesi outperforming, with sales rising over three times industry average

11-10-2011

Italian drugmaker Chiesi’s commitment to innovation and scientific collaboration continues to deliver…

Chiesi FarmaceuticiFinancialPharmaceuticalResearch

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top